Switch to:
Also traded in: Germany, Italy, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 2.92
CTIC's Cash-to-Debt is ranked lower than
63% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. CTIC: 2.92 )
Ranked among companies with meaningful Cash-to-Debt only.
CTIC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.3 Max: No Debt
Current: 2.92
Equity-to-Asset 0.23
CTIC's Equity-to-Asset is ranked lower than
84% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. CTIC: 0.23 )
Ranked among companies with meaningful Equity-to-Asset only.
CTIC' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.7  Med: 0.05 Max: 0.95
Current: 0.23
-2.7
0.95
Piotroski F-Score: 5
Altman Z-Score: -41.20
Beneish M-Score: -0.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -117.16
CTIC's Operating Margin % is ranked lower than
59% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. CTIC: -117.16 )
Ranked among companies with meaningful Operating Margin % only.
CTIC' s Operating Margin % Range Over the Past 10 Years
Min: -123250  Med: -12650.83 Max: -117.16
Current: -117.16
-123250
-117.16
Net Margin % -119.58
CTIC's Net Margin % is ranked lower than
61% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. CTIC: -119.58 )
Ranked among companies with meaningful Net Margin % only.
CTIC' s Net Margin % Range Over the Past 10 Years
Min: -169773.75  Med: -13740.68 Max: -119.58
Current: -119.58
-169773.75
-119.58
ROE % -250.54
CTIC's ROE % is ranked lower than
93% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. CTIC: -250.54 )
Ranked among companies with meaningful ROE % only.
CTIC' s ROE % Range Over the Past 10 Years
Min: -1009.15  Med: -275.8 Max: -122.21
Current: -250.54
-1009.15
-122.21
ROA % -70.56
CTIC's ROA % is ranked lower than
78% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. CTIC: -70.56 )
Ranked among companies with meaningful ROA % only.
CTIC' s ROA % Range Over the Past 10 Years
Min: -271.76  Med: -122.66 Max: -50.09
Current: -70.56
-271.76
-50.09
ROC (Joel Greenblatt) % -1977.49
CTIC's ROC (Joel Greenblatt) % is ranked lower than
75% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. CTIC: -1977.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CTIC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3033.77  Med: -1865.44 Max: -484.17
Current: -1977.49
-3033.77
-484.17
3-Year EBITDA Growth Rate -23.90
CTIC's 3-Year EBITDA Growth Rate is ranked lower than
75% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. CTIC: -23.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CTIC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -83.6  Med: -23.9 Max: 32.2
Current: -23.9
-83.6
32.2
3-Year EPS without NRI Growth Rate -26.60
CTIC's 3-Year EPS without NRI Growth Rate is ranked lower than
76% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CTIC: -26.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CTIC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -83.3  Med: -26.6 Max: 21.4
Current: -26.6
-83.3
21.4
GuruFocus has detected 1 Warning Sign with CTI BioPharma Corp $CTIC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CTIC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CTIC Guru Trades in Q1 2016

Paul Tudor Jones 188,500 sh (New)
Jim Simons 12,200 sh (New)
» More
Q2 2016

CTIC Guru Trades in Q2 2016

Jim Simons 315,544 sh (+2486.43%)
Paul Tudor Jones Sold Out
» More
Q3 2016

CTIC Guru Trades in Q3 2016

Jim Simons 1,966,847 sh (+523.32%)
» More
Q4 2016

CTIC Guru Trades in Q4 2016

Jim Simons 1,740,491 sh (-11.51%)
» More
» Details

Insider Trades

Latest Guru Trades with CTIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:VVUS, NAS:AQB, NAS:CXRX, OTCPK:CTIX, NAS:INFI, NAS:ATHX, NAS:MDWD, NAS:GNCA, OTCPK:TRGNF, OTCPK:HPPI, NAS:PPHM, NAS:PSTI, NAS:APEN, OTCPK:MCUJF, OTCPK:BCDA, NAS:EVGN, NAS:CDXC, NAS:NVIV, OTCPK:CYDY, OTCPK:IMMVF » details
Traded in other countries:CEPS.Germany, CTIC.Italy, 0RLB.UK,
CTI Biopharma Corp is a biopharmaceutical company. The Company is engaged in acquiring, developing & bringing market less toxic, more effective therapies to treat and cure cancer.

CTI Biopharma Corp was incorporated in Washington in 1991. It is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer benefit to patients and health care providers. It is currently concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, it is primarily focused on commercializing PIXUVRI in select countries in the European Union, or the E.U., for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, or NHL, and evaluating pacritinib for the treatment of adult patients with myelofibrosis. The Company faces competition from a variety of companies focused on developing oncology drugs. It competes with large pharmaceutical companies and with other specialized biotechnology companies. The Company is subject to extensive regulation by the FDA and other federal, state, and local regulatory agencies.

Ratios

vs
industry
vs
history
PB Ratio 3.51
CTIC's PB Ratio is ranked higher than
55% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. CTIC: 3.51 )
Ranked among companies with meaningful PB Ratio only.
CTIC' s PB Ratio Range Over the Past 10 Years
Min: 0.84  Med: 3.37 Max: 54.97
Current: 3.51
0.84
54.97
PS Ratio 0.93
CTIC's PS Ratio is ranked higher than
95% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. CTIC: 0.93 )
Ranked among companies with meaningful PS Ratio only.
CTIC' s PS Ratio Range Over the Past 10 Years
Min: 0.3  Med: 2.93 Max: 1676.47
Current: 0.93
0.3
1676.47
EV-to-EBIT 0.57
CTIC's EV-to-EBIT is ranked higher than
90% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 18.89 vs. CTIC: 0.57 )
Ranked among companies with meaningful EV-to-EBIT only.
CTIC' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.7  Med: -0.3 Max: 0.7
Current: 0.57
-3.7
0.7
EV-to-EBITDA 0.58
CTIC's EV-to-EBITDA is ranked higher than
91% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 16.23 vs. CTIC: 0.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
CTIC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5  Med: -0.3 Max: 0.7
Current: 0.58
-5
0.7
Current Ratio 1.47
CTIC's Current Ratio is ranked lower than
77% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. CTIC: 1.47 )
Ranked among companies with meaningful Current Ratio only.
CTIC' s Current Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.49 Max: 24.99
Current: 1.47
0.38
24.99
Quick Ratio 1.41
CTIC's Quick Ratio is ranked lower than
73% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. CTIC: 1.41 )
Ranked among companies with meaningful Quick Ratio only.
CTIC' s Quick Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.49 Max: 24.96
Current: 1.41
0.38
24.96
Days Inventory 785.18
CTIC's Days Inventory is ranked lower than
100% of the 314 Companies
in the Global Biotechnology industry.

( Industry Median: 129.42 vs. CTIC: 785.18 )
Ranked among companies with meaningful Days Inventory only.
CTIC' s Days Inventory Range Over the Past 10 Years
Min: 15.15  Med: 1080.1 Max: 9020.25
Current: 785.18
15.15
9020.25
Days Sales Outstanding 3.76
CTIC's Days Sales Outstanding is ranked higher than
94% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. CTIC: 3.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
CTIC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.47  Med: 21.79 Max: 834.94
Current: 3.76
2.47
834.94
Days Payable 3.00
CTIC's Days Payable is ranked lower than
94% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 56.51 vs. CTIC: 3.00 )
Ranked among companies with meaningful Days Payable only.
CTIC' s Days Payable Range Over the Past 10 Years
Min: 3  Med: 2592.11 Max: 49126.02
Current: 3
3
49126.02

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -36.70
CTIC's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. CTIC: -36.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CTIC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -413.6  Med: -36.7 Max: 0
Current: -36.7
-413.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 22.20
CTIC's Price-to-Net-Cash is ranked lower than
76% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. CTIC: 22.20 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CTIC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.45  Med: 2.44 Max: 22.2
Current: 22.2
1.45
22.2
Price-to-Net-Current-Asset-Value 6.83
CTIC's Price-to-Net-Current-Asset-Value is ranked higher than
50% of the 387 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. CTIC: 6.83 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CTIC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.18  Med: 3.9 Max: 95
Current: 6.83
1.18
95
Price-to-Tangible-Book 3.52
CTIC's Price-to-Tangible-Book is ranked higher than
64% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CTIC: 3.52 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CTIC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.79  Med: 2.1 Max: 82.97
Current: 3.52
0.79
82.97
Price-to-Median-PS-Value 0.32
CTIC's Price-to-Median-PS-Value is ranked higher than
88% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. CTIC: 0.32 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CTIC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1  Med: 0.42 Max: 570
Current: 0.32
0.1
570
Earnings Yield (Greenblatt) % 175.91
CTIC's Earnings Yield (Greenblatt) % is ranked higher than
97% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. CTIC: 175.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CTIC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 144.1  Med: 478.35 Max: 2145.9
Current: 175.91
144.1
2145.9

More Statistics

Revenue (TTM) (Mil) $59.59
EPS (TTM) $ -2.70
Beta0.98
Short Percentage of Float3.97%
52-Week Range $3.07 - 6.48
Shares Outstanding (Mil)28.23

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) -0.78
EPS without NRI ($) -0.78
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CTIC

Headlines

Articles On GuruFocus.com
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar G Mar 24 2014 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Feb 25 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Jan 28 2011 
Weekly CEO Sells Highlight: CTIC, DDR, UNM, BRCM, TC Jan 09 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 250,000 Shares Jan 03 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 200,000 Shares Dec 17 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 150,000 Shares Dec 10 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 100,000 Shares Nov 05 2010 

More From Other Websites
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Feb 27 2017
5:12 am CTI BioPharma names Adam Craig, M.D., Ph.D., as President and CEO effective March 20 Feb 27 2017
CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D.,... Feb 27 2017
CTI BioPharma to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017 Feb 23 2017
CTI BIOPHARMA CORP Files SEC form 8-K, Other Events Feb 10 2017
CTI BioPharma to Present at the BIO CEO & Investor Conference Feb 08 2017
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 31 2017
CTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jan 24 2017
CTI BioPharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors Jan 24 2017
CTI BIOPHARMA CORP Files SEC form 8-K, Other Events Jan 20 2017
Latest Reports on Recent Market Movers: 3D Systems and CTI BioPharma Jan 10 2017
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 09 2017
CTI BioPharma Announces Progress Of Lead Programs And Strategic Objectives For 2017 Jan 09 2017
CTI Biopharma stock revived after FDA ruling, reverse stock split Jan 06 2017
CTI BIOPHARMA CORP Files SEC form 8-K, Material Modification to Rights of Security Holders Jan 05 2017
CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib Jan 05 2017
ETFs with exposure to CTI BioPharma Corp. : January 4, 2017 Jan 04 2017
CTI BioPharma Corp. breached its 50 day moving average in a Bullish Manner : CTIC-US : January 4,... Jan 04 2017
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Dec 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)